Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 With or Without PD-1 Monoclonal Antibody in High-Risk Locally Advanced Nasopharyngeal Carcinoma
NCT07797881Phase 2Not yet recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 2, randomised trial of izalontamab brengitecan in nasopharyngeal carcinoma (NPC) (3 arms), sponsored by Biokin Pharmaceutical. Primary endpoint: Complete Response Rate at 24 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07797881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07797881.